Additionally, therapeutic strategies targeting this pathway—such as KMO inhibitors, KYNA analogs, or antioxidant adjuvants—warrant exploration for their potential to mitigate diabetes-associated ocular disease. This evidence concerns the gene KMO and diabetes mellitus.